Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna Laser Neurolysis Coverage Policy Update | Op…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0552

    Laser Neurolysis (Laser Peripheral Nerve Block)

    Customize your policy alerts

    Sign up for Aetna Policy 0552 alerts

    Get alerted when Policy 0552 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna's coverage stance on laser neurolysis (noninvasive laser application to peripheral nerves) and lists indications considered experimental, investigational, or unproven. It affects providers seeking coverage for laser neurolysis procedures for members.

    Policy Summary
    PayerAetna
    PolicyLaser Neurolysis (Laser Peripheral Nerve Block)
    Policy CodePolicy 0552
    Change TypeNo material changes
    Effective DateAug 14, 2001
    Last ReviewJun 10, 2027
    Next Review DateJun 10, 2027
    Key ActionReference the policy's listed CPT/ICD-10 codes and note that laser neurolysis for the specified indications is considered experimental and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5indications listed as experimental/unproven
    1997-2026study year range cited
    18RCTs in cited review
    0552policy number

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Determinations

    Experimental, Investigational, or Unproven

    Aetna considers laser peripheral nerve block (laser neurolysis) experimental, investigational, or unproven for the following indications (not an all‑inclusive list):

    Listed indications considered experimental/investigational/unproven: 1. Carpal tunnel syndrome 2. Complex regional pain syndrome 3. Facet joint pain 4. Phantom limb pain 5. Sacroiliac joint pain

    These indications are examples given in the policy; the list is not all-inclusive.

    Aetna considers laser peripheral nerve block (laser neurolysis) experimental, investigational, or unproven because there is insufficient evidence regarding its effectiveness for the indications listed. The policy specifically identifies examples where evidence is limited or lacking — including carpal tunnel syndrome, complex regional pain syndrome (CRPS), facet joint pain, phantom limb pain, and sacroiliac joint pain — and therefore does not support routine coverage for these uses.

    Certain ICD-10 diagnosis codes are identified as not covered when used to support claims for the indications listed in this Clinical Policy Bulletin. Examples of such codes include codes for phantom limb syndrome with pain (G54.6), carpal tunnel syndrome (G56.00–G56.03), causalgia/CRPS II (G56.40–G56.42; G57.70–G57.73), CRPS I (G90.50–G90.59), and sacroiliac joint pain (M53.3). Providers should reference the policy’s listed ICD-10 codes when preparing authorization requests or claims submissions.

    Relevant Procedure and Diagnosis Codes

    Related CPT codesCPT
    64600 - 64610Destruction by neurolytic agent, trigeminal nerve
    64620 - 64640Destruction by neurolytic agent, intercostal nerve, paravertebral facet joint nerve, or pudendal nerve
    64702 - 64704Neuroplasty, digital, one or both, same digit or nerve of hand or foot
    64708 - 64714Neuroplasty, major peripheral nerve, arm or leg, open
    64727Internal neurolysis, requiring the use of operating microscope (List separately in addition to code for neuroplasty)
    ICD-10 codes noted as not covered for listed indicationsICD-10Not Covered
    G54.6Phantom limb syndrome with pain
    G56.00 - G56.03Carpal tunnel syndrome
    G56.40 - G56.42Causalgia of upper limb [Complex regional pain syndrome II of upper limb]
    G57.70 - G57.73Causalgia of lower limb [Complex regional pain syndrome II of lower limb]
    G90.50 - G90.59Complex regional pain syndrome I (CRPS I) [Complex regional pain syndrome I of upper and lower limb]
    M53.0Cervicocranial syndrome
    M53.3Sacrococcygeal disorders, not elsewhere classified [sacroiliac joint pain]
    M53.82 - M53.83Other specified dorsopathies cervical and cervicothoracic region
    M54.2Cervicalgia
    M54.50 - M54.59Low back pain
    1–10 of 11
    1/2

    Provider Requirements and Billing Notes

    Prior Authorization

    Include listed CPT/HCPCS and ICD-10 codes with authorization/claims

    When seeking authorization or submitting claims, include the procedure (CPT/HCPCS) and diagnosis (ICD-10) codes listed in the policy. Relevant procedure codes include 64600–64610; 64620–64640; 64702–64704; 64708–64714; and 64727. The policy also lists specific ICD-10 diagnosis codes that are not covered for the indications in this bulletin (see ICD-10 group).

    • CPT/HCPCS procedure codes: 64600-64610; 64620-64640; 64702-64704; 64708-64714; 64727
    • ICD-10 diagnosis codes identified as not covered: G54.6; G56.00–G56.03; G56.40–G56.42; G57.70–G57.73; G90.50–G90.59; M53.0; M53.3; M53.82–M53.83; M54.2; M54.50–M54.59; M54.6
    Step Therapy

    Require trial of conservative/established therapies before experimental laser neurolysis

    The policy notes limited and low-quality evidence for laser therapy and references systematic review evidence (Cochrane) for CRPS physiotherapy; established conservative therapies such as physiotherapy, graded motor imagery, and mirror therapy are the preferred, evaluated approaches before considering experimental treatments like laser neurolysis.

    • Cochrane review (Smart et al.) found low or very low quality evidence for physiotherapy interventions in CRPS (18 RCTs; 739 participants).
    • Aetna considers laser neurolysis experimental, investigational, or unproven for listed indications, implying conservative/established therapies should be tried first.
    Documentation Required

    Coding and documentation reminders for neurolytic/neuroplasty procedures

    Document and code neurolytic/neuroplasty procedures precisely and note the policy’s ICD-10 exclusions; include the specific CPT codes for neurolysis/neuroplasty and use diagnosis codes consistent with the member’s condition but avoid ICD-10 codes the policy identifies as not covered for these indications.

    • Use procedure codes 64600–64610; 64620–64640; 64702–64704; 64708–64714; 64727 for neurolytic and neuroplasty procedures as applicable.
    • Do not report ICD-10 codes listed as not covered (see policy list) when seeking coverage for laser neurolysis for the listed indications.
    Denial Risk

    Denial risk: listed indications are considered experimental/investigational

    Claims for laser peripheral nerve block (laser neurolysis) for the indications listed in this policy are considered experimental, investigational, or unproven and may be denied on that basis.

    • Listed example indications at risk for denial include: carpal tunnel syndrome; complex regional pain syndrome; facet joint pain; phantom limb pain; sacroiliac joint pain.

    Preference for Conservative or Established Therapies

    Conservative Treatment Requirements

    Implied preference for conservative or established therapies before considering experimental interventions such as laser neurolysis:

    Conservative/established therapies preferred: Providers should consider established conservative therapies (for example: physiotherapy interventions such as graded motor imagery, mirror therapy, therapeutic exercise, manual therapy, and other standard physiotherapist‑delivered strategies) which have at least some evidence of benefit in conditions like complex regional pain syndrome prior to experimental interventions like laser neurolysis.

    This policy references systematic review evidence indicating limited and low‑quality data for physiotherapy interventions overall and small/low‑quality evidence for laser therapy; therefore conservative treatments are the standard approaches evaluated in reviews.

    Imaging / Procedural Requirements

    Note

    No imaging requirement specified for laser neurolysis

    No imaging or fluoroscopic guidance requirement is specified for laser denervation / laser neurolysis in this policy; studies cited describe targeting anatomy (e.g., dorsal facet capsule) but do not mandate imaging.

    • Policy states imaging requirements for laser neurolysis: none specified.

    Background

    Laser neurolysis refers to the noninvasive application of laser to peripheral nerves and is considered a form of low‑level laser therapy. It has primarily been investigated in small, uncontrolled studies for conditions such as carpal tunnel syndrome and facet joint denervation; overall, the available studies are limited by small sample sizes, short follow‑up, and lack of rigorous controls, contributing to the policy’s conclusion that effectiveness is not established.

    Definitions

    Laser neurolysis — definition and key facts
    TermLaser neurolysis
    DefinitionThe non-invasive application of laser to peripheral nerves (a form of low-level laser therapy).
    Typical use investigatedPrimarily investigated for treatment of carpal tunnel syndrome in small, uncontrolled studies.
    Example treatment parameters (reported study)Gallium aluminum arsenide infrared continuous laser, 830 nm wavelength, 30 mW output; 9 Joules per point at 5 points along the median nerve; 15 treatments.
    Evidence limitationsExisting studies are limited by small sample sizes, short duration, and lack of control groups.

    Not Covered Indications

    NOT COVERED: Laser peripheral nerve block (laser neurolysis) is not covered for the listed indications, including but not limited to carpal tunnel syndrome, complex regional pain syndrome (CRPS), facet joint pain, phantom limb pain, and sacroiliac joint pain. Claims submitted for these indications may be denied as the procedure is considered experimental, investigational, or unproven; providers should also note the policy’s list of ICD-10 diagnosis codes that are not covered when submitting claims.

    Policy Summary
    PayerAetna
    PolicyLaser Neurolysis (Laser Peripheral Nerve Block)
    Policy CodePolicy 0552
    Change TypeNo material changes
    Effective DateAug 14, 2001
    Last ReviewJun 10, 2027
    Next Review DateJun 10, 2027
    Key ActionReference the policy's listed CPT/ICD-10 codes and note that laser neurolysis for the specified indications is considered experimental and may be denied.
    SourceLink
    On This Page
    Coverage DeterminationsRelevant Procedure and Diagnosis CodesProvider Requirements and Billing NotesPreference for Conservative or Established TherapiesImaging / Procedural RequirementsBackgroundDefinitionsNot Covered Indications